as declared in business-standard
Zydus partners with Japan's Takeda to develop vaccine for chikungunya
Zydus partners with Japan's Takeda to develop vaccine for chikungunya
Zydus partners with Japan's Takeda to develop vaccine for chikungunyaEarly stage project will develop a vaccine for chikungunya, for which there is currently no vaccine or medicine to treat itThe Ahmedabad-based has entered into a partnership agreement with Japan's Company Limited to develop for chikungunya, an emerging infectious disease.At present, there is no to prevent or medicine to treat infection.The broad-based agreement between the two companies includes early stage development to the final commercialisation of the vaccine.
not to mention fiercepharma
As India's Chikungunya epidemic spreads, Zydus and Takeda partner on search for a vaccine
As India's Chikungunya epidemic spreads, Zydus and Takeda partner on search for a vaccine
With India in the throes of an outbreak of Chikungunya, local drugmaker Zydus Cadila has stepped up to develop a vaccine against the crippling viral disease--with help from Japan's Takeda.The project is still in its infancy, but it will cover a Chikungunya candidate from early-stage development through commercialization.There are currently no effective drugs or vaccines for the virus, which causes fever and severe joint pain, and is steadily spreading around the globe.
as well livemint
Zydus partners Takeda to develop, market vaccine for chikungunya
Zydus partners Takeda to develop, market vaccine for chikungunya
Cadila, which is into vaccine research, has developed and markets H1N1 vaccine, and has been developing vaccine candidates to address infectious diseases like influenza, leishmaniasis, measles-mumps-rubella-varicella (MMR), typhoid and hepatitis B.Hyderabad: Cadila Healthcare Ltd, a part of Zydus Cadila group, on Tuesday said it has partnered with Japanese drug maker Takeda Pharmaceutical Co. Ltd to develop and commercialise a vaccine against chikungunya.The broad-based agreement includes early-stage development to the final commercialisation of the vaccine.The terms of the agreement were not disclosed.
No comments:
Post a Comment